Christopher O’Donnell
Directeur/Membre du Conseil chez Adapsyn Bioscience, Inc.
Profil
Christopher O'Donnell , PHD is Executive Director, WRDM and Partner at Pfizer Ventures.
Chris is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer.
He currently has responsibility for Pfizer’s investments in Adapsyn, Bioscience Arkuda Therapeutics, Arrakis Therapeutics, Mitokinin, Parthenon Therapeutics, Pyxis Oncology (PYXS), Storm Therapeutics, and Strata Oncology.
He is also responsible for managing our investment in the Mission BioCapital and Phoenix Venture Partners funds.
His prior investment responsibilities include BioAtla (BCAB), Kymera Therapeutics (KYMR), Morphic Therapeutic (MORF) and Petra Pharma.
Chris brings 20+ years of scientific leadership, a strong track record of delivering clinical candidates across multiple disease areas and modalities, and proven ability to build and lead highly engaged teams.
He built and led the Applied Synthesis Technologies group within R&D to help accelerate the delivery of Pfizer’s small molecule portfolio.
Prior to that, Chris built and led Pfizer’s Antibody Drug Conjugate Oncology Medicinal Chemistry group which delivered new linker, payload and conjugation methods resulting in over 7 conjugates entering clinical development.
Chris started his career in the Neuroscience Medicinal Chemistry group where he invented and helped deliver numerous clinical candidates.
Chris received his BS in Chemistry from the University of Illinois-Urbana/Champaign and his PhD in Chemistry from the University of Wisconsin-Madison and joined Pfizer after completing post-doctoral studies at the University of California - Irvine
Postes actifs de Christopher O’Donnell
| Sociétés | Poste | Début |
|---|---|---|
Adapsyn Bioscience, Inc.
 Adapsyn Bioscience, Inc. BiotechnologyHealth Technology Adapsyn Bioscience, Inc. operates as a biotechnology company focussed on the discovery and development of novel medicines. The company was founded by Nathan Magarvey and is headquartered in Hamilton, Canada. | Directeur/Membre du Conseil | - |
Arkuda Therapeutics, Inc.
 Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Pfizer Venture Investments LLC
 Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Private Equity Investor | 01/03/2018 |
STORM Therapeutics Ltd.
 STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | - |
Strata Oncology, Inc.
 Strata Oncology, Inc. Pharmaceuticals: MajorHealth Technology Strata Oncology, Inc. manufactures oncology drugs. It provides comprehensive testing, portfolio of treatments, peace of mind. The company was founded by Daniel D. Rhodes, Scott Tomlin and Keith T. Flaherty in 2015 and is headquartered Ann Arbor, MI. | Directeur/Membre du Conseil | - |
Incendia Therapeutics, Inc.
 Incendia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Incendia Therapeutics, Inc. develops a novel class of anti-cancer therapies. The company is based in Boston, MA. The company was founded in 2003 by Laurent Audoly, Colin Glenn Begley, Olga Granaturova, Guy Travis Clifton. Laurent Audoly has been the CEO since 2003. | Directeur/Membre du Conseil | - |
Santi Therapeutics, Inc.
 Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Christopher O’Donnell
| Sociétés | Poste | Fin |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Directeur/Membre du Conseil | 01/10/2021 |
| KYMERA THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Formation de Christopher O’Donnell
| University of Illinois At Urbana–Champaign | Undergraduate Degree |
| University of Wisconsin | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KYMERA THERAPEUTICS, INC. | Health Technology |
| PYXIS ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Adapsyn Bioscience, Inc.
Adapsyn Bioscience, Inc. BiotechnologyHealth Technology Adapsyn Bioscience, Inc. operates as a biotechnology company focussed on the discovery and development of novel medicines. The company was founded by Nathan Magarvey and is headquartered in Hamilton, Canada. | Health Technology |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | Health Technology |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Finance |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Strata Oncology, Inc.
Strata Oncology, Inc. Pharmaceuticals: MajorHealth Technology Strata Oncology, Inc. manufactures oncology drugs. It provides comprehensive testing, portfolio of treatments, peace of mind. The company was founded by Daniel D. Rhodes, Scott Tomlin and Keith T. Flaherty in 2015 and is headquartered Ann Arbor, MI. | Health Technology |
Incendia Therapeutics, Inc.
Incendia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Incendia Therapeutics, Inc. develops a novel class of anti-cancer therapies. The company is based in Boston, MA. The company was founded in 2003 by Laurent Audoly, Colin Glenn Begley, Olga Granaturova, Guy Travis Clifton. Laurent Audoly has been the CEO since 2003. | Health Technology |
Santi Therapeutics, Inc.
Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA. | Health Technology |